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Abstract
Objectives: Recent evidence showed that myotonic dystrophy type I (DM1)
patients are at increased risk of certain cancers, but the risk of benign tumors is
unknown. We compared the risk of benign tumors in DM1 patients with
matched DM1-free individuals and assessed the association between benign
tumors and subsequent cancers. Methods: We identified 927 DM1 patients and
13,085 DM1-free individuals matched on gender, birth-year, clinic, and clinic-
registration year from the UK Clinical Practice Research Datalink, a primary
care records database. We used Cox regression models for statistical analyses.
Results: DM1 patients had elevated risks of thyroid nodules (Hazard Ratio
[HR] = 10.4; 95% Confidence Interval [CI] = 3.91–27.52; P < 0.001), benign
tumors of the brain or nervous system (HR = 8.4; 95% CI = 2.48–28.47;
P < 0.001), colorectal polyps (HR = 4.3; 95% CI = 1.76–10.41; P = 0.001), and
possibly uterine fibroids (HR = 2.7; 95% CI = 1.22–5.88; P = 0.01). Pilomatri-
comas and salivary gland adenomas occurred almost exclusively in DM1
patients (Fisher’s exact P < 0.001). The HR for colorectal polyps was elevated
in DM1 males but not in females (HR = 8.2 vs. 1.3, respectively; P-heterogene-
ity < 0.001), whereas endocrine and brain tumors occurred exclusively in
females. The data suggested an association between benign tumors and subse-
quent cancer in classic DM1 patients (HR = 2.7; 95% CI = 0.93–7.59;
P = 0.07). Interpretation: Our study showed a similar site-specific benign
tumor profile to that previously reported for DM1-associated cancers. The pos-
sible association between benign tumors and subsequent cancer in classic DM1
patients warrants further investigation as it may guide identifying patients at
elevated risk of cancer. Our findings underscore the importance of following
population-based screening recommendations in DM1 patients, for example,
for colorectal cancer.
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Introduction
Myotonic dystrophy type I (Dystrophia Myotonica I;
DM1; Steinert’s disease) is an autosomal dominant multi-
system disorder, primarily presenting with progressive
muscle weakness and myotonia.1,2 It is one of the most
common adult-onset muscular dystrophies, with an esti-
mated prevalence ranging from 5 to 20 per 100,000
worldwide.3 DM1 results from a CTG tri-nucleotide
repeat expansion in the 3’ untranslated region of the dys-
trophia myotonica protein kinase (DMPK) gene on chro-
mosome 19q13.3.4–6 Clinically, the DM1 phenotype varies
widely and is classified into three major subtypes: congen-
ital/childhood (most severe), classic, and late-onset
(mild).2 Recent quantitative studies have shown that
DM1 patients are at increased risk of cancers arising in
the skin, thyroid, uterus, and possibly colon, testis, and
brain.7–13 We have previously shown that the excess risk
of cancer in DM1 may be restricted to patients with the
classic subtype (diagnosed between ages 11–40 years).14
Case reports as early as 1965 suggested an association
between certain benign tumors and DM1, most com-
monly pilomatricoma, a rare calcifying cutaneous neo-
plasm.15 Other reported benign tumors included those
arising in the parotid, parathyroid, thyroid, and pituitary
glands, as well as thymoma, meningioma, uterine fibroids,
and insulinoma (reviewed by Mueller et al.15). Cross-sec-
tional studies of 255 Italian16 and 231 United Kingdom
(UK)17 DM1 patients reported overall benign tumor fre-
quencies of approximately 21% and 12%, respectively,
with female reproductive tumors most commonly
reported. Another Italian study in which dermatological
examinations were conducted in 90 DM1 patients and
103 age- and gender-matched controls found that DM1
patients were more likely to have dysplastic nevi and pilo-
matricoma.18 Finally, a Spanish study found an increased
risk of pilomatricoma in 102 DM1 patients versus age-
and gender-matched controls.19
In this study, we aimed to evaluate organ site-specific
benign tumor risk in a large cohort of DM1 patients
compared with matched DM1-free individuals (control
cohort). We also evaluated the association between benign
tumors and subsequent cancer in both cohorts.
Methods
The study design was previously described.12,14 Briefly, we
utilized the UK Clinical Practice Research Datalink
(CPRD), a primary care physician database linkable to
other data sources and identified 927 patients with a
record of DM1 (defined using Read codes “F392011:
Steinert’s disease”, and “F392000: Dystrophia myotonica
[Steinert’s disease]”) from the October 2016 CPRD
release, and 13,085 DM1-free controls matched on year of
birth (2 years), gender, clinic, and clinic registration
year (1 year). All participants were cancer-free prior to
the start of follow-up. With the exception of cancer, all
study variables were identified from CPRD using Read
codes (available upon request). Cancer cases were identi-
fied from CPRD (n = 525), linkable inpatient records
from the national Hospital Episode Statistics database
(HES; n = 213), or cause of death data from the Office of
National Statistics (ONS; n = 14), as previously
described.14
Statistical analysis
Cox proportional hazards regression models were used to
assess the association between developing benign tumors
(overall and by anatomic site) and DM1 status (DM1-af-
fected vs. DM1-free matched controls). Age was the time
scale used for all analyses. Follow-up started at the latest
of either age at first DM1-diagnosis/DM1-free selection,
clinic registration, or study start date (January 1st, 1988;
after the start of CPRD). Patients were followed to the
earliest of either age at first benign tumor under study,
death, transfer out of the CPRD-participating clinic, last
data collection in CPRD, or end of study (February 29,
2016). To accommodate the matched design, baseline
hazards were stratified on the matched sets. Potential
effect measure modification was assessed by fitting sepa-
rate Cox models to strata defined by gender and DM1
subtype categories (using age at DM1 diagnosis as a
proxy; age 0–10 years = congenital/childhood, 11–
40 years = classic, and >40 years = late-onset). Hetero-
geneity of estimates across strata was tested using the
Wald test. The proportional hazards assumption was
assessed using Schoenfeld residuals; no significant viola-
tions were observed. When Cox models failed due to zero
or sparse events, we used Fisher’s exact test to examine
intergroup differences.
To assess the robustness of our findings, we conducted
several sensitivity analyses using more stringent defini-
tions of DM1. We repeated the analysis using only: (1)
DM1 patients diagnosed after their clinic’s “up-to-stan-
dard” date (a CPRD practice-level data quality metric);20
(2) DM1 patients diagnosed in 1995 or later (after DM1
gene discovery in 1992 and subsequent implementation of
DM1 genetic testing in the UK);21 and (3) DM1 patients
who had a DM1 record in at least two of the three data
sources (CPRD primary care database, HES, and ONS).
Additionally, we conducted a sensitivity analysis ending
follow-up at the maximum of three years (median follow-
up in the DM1-free control group) for all patients, to
assess whether differential follow-up time for the DM1
and DM1-free cohorts affected our results. Finally, to
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address the possibility of detection bias, we adjusted all
models for the number of healthcare encounters and indi-
cators of health seeking behavior. The number of health-
care encounters were ascertained from CPRD and/or HES
(maximum of one per day) as a continuous, time-varying
covariate with a one-year time lag, and were counted in
12-month intervals between start of follow-up and censor
or first benign tumor dates. Indicators of health-seeking
behavior in this study included participation in cancer
screening or influenza vaccination identified from CPRD
records. In all analyses, we only used the corresponding
matched DM1-free controls for included DM1 patients.
Cox proportional hazards regression models were also
used to evaluate the association between benign tumors
and subsequent cancer risk in DM1 patients and the
DM1-free cohort, separately. Benign tumor was consid-
ered a time-dependent variable, in which study partici-
pants belonged to the benign tumor-free group until they
developed their first benign tumor. Final models were
adjusted for gender and number of healthcare care
encounters as described above. To adjust for cancer ascer-
tainment from multiple databases for patients eligible for
linkage, the regression models were additionally adjusted
for linkage status as a time-varying covariate.
We conducted all analyses using SAS version 9.4 (Cary,
NC) and R version 3.3.1 (R Foundation for Statistical
Computing, Vienna, Austria). For site-specific benign
tumor risk analyses, we defined statistical significance as
P-value < 0.01 to minimize the possibility of false discov-
ery; for all others, P-value < 0.05 was used.
This study was approved by the CPRD Independent
Scientific Advisory Committee (Protocol # 16_005RA2);
see Acknowledgments for details on data sources. The use
of the CPRD database was exempted from full Institu-
tional Review Board (IRB) review by the National Insti-
tutes of Health Office of Human Subject Research and
the University of Maryland’s IRB, because of the anon-
ymized nature of the data.
Role of the funding source
The funding source had no role in the design, conduct,
or reporting of the study.
Results
Table 1 summarizes the study cohort characteristics. Dur-
ing 80,177 person-years of follow-up, we observed 138
benign tumors in 132 (14%) DM1 patients and 844 benign
tumors in 800 (6%) DM1-free controls. Skin tumors com-
prised the most frequent diagnosis in both cohorts
(DM1 = 85/132 [64%]; DM1-free = 623/844 [78%]), fol-
lowed by female genital tumors (DM1 = 11%; DM1-
free = 10%), digestive tract tumors (DM1 = 8%; DM1-
free = 5%), endocrine tumors (DM1 = 7%, DM1-
free = 2%), and brain or nervous system tumors (including
cerebral meningiomas, neuromas, neurofibromas, and
other unspecified benign neoplasms; DM1 = 5%; DM1-
free = 1%). In DM1, 89% of endocrine tumors were thy-
roid nodules or cysts, 79% of female genital tumors were
uterine fibroids, all digestive tumors were colorectal polyps,
and all salivary gland tumors were pleomorphic adenomas
(see Table 2 footnote for details of tumor subtypes).
The age at first benign tumor diagnosis was similar in
DM1 patients (median = 43 years, range = 14–81) and
DM1-free controls (mean = 42 years, range = 3–90)
(P = 0.27). However, site-specific differences were noted.
Specifically, DM1 patients developed colorectal polyps at
a younger age compared with DM1-free controls (median
age at first polyp: DM1 = 50 years [range = 14–81] vs.
DM1-free = 65 years [range = 33–78], P = 0.04). Simi-
larly, age differences were observed for tumors of the
brain and nervous system (median age DM1 = 48 years,
range = 16–59 vs. DM1-free = 59 years, range = 42–63;
P = 0.05) and thyroid nodules (median age
DM1 = 50 years, range = 28–70 vs. DM1-free = 63,
range = 30–83, P = 0.16), although these differences were
not statistically significant. No differences were noted for
uterine fibroids (median age DM1 = 44 years, range =
37–53 vs. DM1-free = 45, range = 29–65, P = 0.87), or
other sites (Fig. 1).
Table 1. Characteristics of the myotonic dystrophy type I (DM1)-af-
fected patients and their matched DM1-free controls.
Characteristics DM1 (n = 927) DM1-free (n = 13,085)




Classic (11–40 years) 500 (54%) –
Late-onset (>40 years) 295 (32%) –




Male 455 (49%) 6,474 (49%)
Female 472 (51%) 6,611 (51%)
Benign tumor
All sites combined, n (%) 132 (14%) 800 (6%)
Age at first tumor,
mean (SD)
43.8 (14.6) 42.0 (15.0)
Tumor status
None 762 (82%) 11,660 (89%)
Benign only 124 (13%) 717 (5%)
Malignant only 33 (4%) 625 (5%)
Benign and malignant 8 (1%) 83 (1%)
Follow-up time
Median (range) 5.6 (0-28.2) 3.7 (0-28.2)
Total, Person-years 7,100.7 73,076.5
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Compared with matched DM1-free controls, DM1
patients were at elevated risk of developing benign tumors
(HR for all sites combined = 1.5; 95% CI = 1.23–1.88;
P < 0.001). The observed excess in risk was driven by thy-
roid nodules (HR = 10.4; 95% CI = 3.91–27.52;
P < 0.001), benign tumors of the brain or nervous system
(HR = 8.4; 95% CI = 2.48–28.47; P < 0.001), colorectal
polyps (HR = 4.3; 95% CI = 1.76–10.41; P = 0.001), and
possibly uterine fibroids (HR = 2.7; 95% CI = 1.22–5.88;
P = 0.01) and skin tumors other than lipoma or pilomatri-
coma (HR = 1.4; 95% CI = 1.08–1.94; 0.01). Pilomatrico-
mas and salivary gland adenomas were found almost
exclusively in DM1 patients, with Fisher’s exact P < 0.001
for both (Table 2).
We found no significant heterogeneity by gender for all
sites combined (P-heterogeneity = 0.93); however, some
site-specific gender differences were observed. An elevated
relative risk of colorectal polyps was noted in males (HR for
DM1 vs. DM1-free = 8.2; 95% CI = 2.70–24.75; P < 0.001;
but not females (HR = 1.3; 95% CI = 0.24–7.28; P = 0.75;
P-heterogeneity < 0.001). In DM1, all benign endocrine
and brain tumors occurred exclusively in females vs. only
74%, and 50%, respectively, occurred in female DM1-free
controls. Pilomatricomas in DM1 occurred primarily in
males (83%). No statistically significant heterogeneity in
the relative risk of benign tumors was noted between strata
defined by DM1 subtype (congenital/childhood, classic,
and late-onset) (P-heterogeneity = 0.75). Results from sen-
sitivity analyses showed similar or higher HRs when
restricting to DM1 patients diagnosed after their clinic’s
up-to-standard date (HR = 1.65, P = 0.001), diagnosed on
or after 1995 (HR = 1.55, P = 0.004), or when ending fol-
low-up at a maximum of 3 years (HR = 1.98, P < 0.001).
In analyses restricted to patients with DM1 records in at
least 2 data sources, the HR was slightly attenuated and did
not reach statistical significance (HR = 1.25; P = 0.19),
likely due to the significant reduction in sample size and/or
over-representation of severe cases (with hospitalization or
death record) (Table 3).
Among DM1 patients, a suggested association between
benign tumors and risk of subsequent cancer (all sites
combined) was only observed in those with the classic
subtype (age at onset = 11–40 years) (HR comparing
patients with benign tumors with those who were tumor-
Table 2. Adjusted hazard ratios and 95% confidence intervals of selected benign tumors comparing myotonic dystrophy type I (DM1)-affected
with matched DM1-free controls.
Tumor/Site
Tumor frequency1 n (%)
HR2 95% CI P-valueDM1 DM1-free
Skin 85 (9.2%) 623 (4.8%)
Lipoma 0.9 0.45 1.86 0.81
Other skin tumors3 1.4 1.08 1.95 0.01
Pilomatricoma – – – <0.0016
Female genital 14 (1.5%) 82 (0.6%)
Uterine fibroids 2.7 1.22 5.88 0.01
Uterine polyps 9.6 1.20 77.49 0.03
Cervical polyps 0.4 0.05 2.96 0.36
Endocrine 9 (1.0%) 19 (0.2%)
Pituitary tumors4 11.0 0.49 250.14 0.13
Thyroid nodules/cysts 10.4 3.91 27.52 <0.001
Digestive 10 (1.1%) 42 (0.3%)
Colorectal polyps 4.3 1.76 10.41 0.001
Other digestive tumors – – – >0.996
Brain & nervous system5 7 (0.8%) 11 (0.1%) 8.4 2.48 28.47 <0.001
Other tumors 13 (1.4%) 67 (0.5%)
Salivary glands – – – <0.0016
Breast fibroadenoma – – – >0.996
Other/Unknown7 1.4 0.67 3.09 0.35
1In accordance with CPRD policy which prohibits the reporting of cells with fewer than five events, frequencies were reported by system, where
applicable.
2Baseline hazards were stratified on the matched sets and models were adjusted for number of healthcare care encounters.
3Skin tumors included nevi, dermatofibromas, papillomas, moles, and other benign neoplasm of the skin.
4In DM1, all pituitary tumors were adenomas; in controls, pituitary tumors included adenomas and craniopharyngiomas.
5Brain & nervous system tumors included meningiomas, neuromas, neurofibromas, and other benign neoplasms of the brain & nervous system.
6Obtained from Fisher’s Exact test due to sparse or zero events in at least one group.
7Other/unknown tumors include tumors of the bone & connective tissue, lip/oral cavity/pharynx, lymphatic/hematopoietic, respiratory, and unspec-
ified sites (total n = 75).
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Figure 1. Distribution of age at diagnosis for selected benign tumors comparing DM1-affected patients with DM1-free controls.
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free = 2.7; 95% CI = 0.93–7.59; P = 0.07 vs. HR in late-
onset DM1 = 0.7; 95% CI = 0.15–3.38; P = 0.67)
(Table 4). No cancers were observed subsequent to benign
tumors in the congenital/childhood DM1 cohort or their
matched controls.
Discussion
In this large study, we demonstrated that DM1 patients
were at elevated risk of developing certain benign tumors,
including pilomatricoma, colorectal polyps, thyroid nod-
ules, salivary gland adenomas, tumors of the brain and
nervous system, and possibly uterine fibroids. We also
found that classic DM1 patients with benign tumors may
be more likely to develop a subsequent cancer, compared
with those who were tumor-free.
Previous studies found DM1 patients to be at elevated
risk of developing specific cancers including melanoma
and basal cell carcinoma of the skin, as well as cancers of
the thyroid, uterus, ovary, and possibly colon, testis, and
brain.7–12,14,22 Here, we identified a similar organ profile
for benign tumors, suggesting that DM1 pathogenesis
could include a selective proliferative cellular growth
advantage in those same organs. Of possible clinical
importance, we found that DM1 patients are at high risk
of developing colorectal polyps at a younger age com-
pared with DM1-free control (median age in years = 50
vs. 65, respectively, P = 0.035). The younger age at col-
orectal polyp in DM1 patients may suggest that this
observation is affected by a detection bias related to the
high prevalence of gastrointestinal abnormalities in DM1
patients. Yet, our observation of a male predominance of
risk argues against detection bias since gastrointestinal
symptoms are more prevalent in female DM1 patients.23
If validated, this suggests that earlier colorectal cancer
screening may warrant consideration for DM1 patients.
Colorectal polypectomy has been proven to reduce colon
cancer risk and mortality in the general population.24,25
Cancer studies in DM were inconclusive in relation to the
risk of colon cancer compared with the general popula-
tion (excess risk in DM patients was suggested in five of
the six published studies, but only one reached statistical
significance7,9–11,14). This inconsistency may be the conse-
quence of differences in colorectal cancer screening prac-
tices between countries. In this study population,
approximately 1% of the DM1 patients developed a col-
orectal cancer, comprising 17% of all DM1 cancers; a sug-
gested increase in cancer risk was observed among
patients with classic DM1 (HR = 1.82, 95% CI = 0.32–
10.31) compared with matched controls (cancer risk find-
ings published previously14). The histopathological classi-
fication of detected polyps in the current study was
unavailable; however, recent data from the English
National Health Service bowel cancer screening program
showed that adenomas represented 67% of all polyps.26
Nonetheless, it is advisable that population-based colorec-
tal cancer screening guidelines be part of the routine,
ongoing care of DM1 patients.
In contrast with our previous study which showed
significant differences in cancer relative risk by DM1 dis-
ease subtype (excess cancer risk was restricted to patients
with classic DM1),14 here we observed no heterogeneity
Table 3. Sensitivity analyses of benign tumor risk estimates (all sites
combined) comparing myotonic dystrophy type I (DM1)-affected





HR 95% CI P-valueDM1 DM1-free
1 71/454 362/5936 1.65 1.22 2.23 0.001
2 55/376 332/5541 1.25 0.89 1.75 0.19
3 72/530 383/6988 1.55 1.16 2.08 0.004
4 42/927 364/13,085 1.98 1.35 2.89 <0.001
1Analyses: (1) Restricted to DM1 patients diagnosed after their clinic’s
“up to standard” date and their matched cohort. (2) Restricted to
DM1 patients with DM1 records in at least two data sources and their
matched cohort. (3) Restricted to DM1 patients diagnosed in 1995 or
later and their matched cohort. (4) Ending follow-up at a maximum
of 3 years for both cohorts.
Table 4. Adjusted hazard ratios of cancer risk (all sites combined) subsequent to benign tumors (all sites combined) in the myotonic dystrophy
type I (DM1)-affected and DM1-free cohorts, stratified by age at DM1 diagnosis.
Cohort
Classic DM1 (age at diagnosis = 11–40 years) Late-onset DM1 (age at diagnosis >40 years)
HR1 95% CI P-value HR1 95% CI P-value
DM1-affected 2.7 0.93 7.59 0.07 0.7 0.15 3.38 0.67
Matched DM1-free controls 1.2 0.70 2.08 0.50 2.0 1.47 2.63 <0.001
P-heterogeneity = 0.01 P-heterogeneity = 0.12
No cancers were observed subsequent to benign tumors in congenital/childhood DM1 patients or their matched controls.
1Hazard ratios of subsequent cancer comparing patients with benign tumors to those who are tumor-free; models were adjusted for gender and
number of healthcare care encounters.
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in the overall risk of benign tumors by disease subtype
(HR for benign tumors in DM1 vs. DM1 free con-
trol = 1.53 in congenital/childhood, 1.92 in classic, and
1.87 in late-onset, P-heterogeneity = 0.62). However, our
analysis exploring the possible association between
benign tumors and the risk of subsequent cancer in
DM1, showed that classic DM1 patients with benign
tumors may be at higher risk of developing cancer com-
pared with those who were tumor-free, an association
that was not observed in late-onset DM1. Although this
finding was not statistically significant, likely due to the
small number of cancer events, it could suggest that
benign tumors in patients with classic DM1 may aid in
identifying patients with a higher genetic predisposition
to tumorigenesis, in general. Due to the relatively small
number of cancer events, we were unable to evaluate
site-specific risks of cancer subsequent to benign tumor.
Larger studies are warranted to investigate these associa-
tions.
Consistent with previous cross-sectional studies of
DM1-associated tumors,16,17,27 benign tumors were more
frequently observed in female DM1-patients (18%) ver-
sus males (10%), with endocrine, brain, and salivary
tumors occurring exclusively in females. In contrast,
most pilomatricomas occurred in male DM1 patients, a
finding consistent with a previous cross-sectional study
of 255 Italian DM1 patients,16 but not with the female
predominance as reported in published literature of
pilomatricomas in the general population.28–33 This
inconsistency may be explained, at least in part, by dif-
ferential healthcare-seeking behavior between males and
females; females, in general, are more likely to visit their
primary care provider,34–38 possibly resulting in higher
detection of pilomatricoma in the general population. In
DM1, we observed a higher frequency in males despite
a similar pattern (average number of healthcare encoun-
ters per year in DM1 females: median = 9.5 vs.
males = 7.8; P < 0.001). Gender-specific phenotypic vari-
ations in DM1 patients have been previously described,
but the biological mechanisms behind such differences
are not known.37 In a small number of DM1 patients,
downregulation of the microRNA 200c/141 tumor sup-
pressor family was reported in women, but a slight ele-
vated expression in men when compared with healthy
controls.11,23
The molecular mechanisms underlying DM1-related
tumorigenesis remain unknown. It has been previously
hypothesized that abnormal accumulation of ß-catenin
through the Wnt/ß-catenin signaling pathway may play
a role in DM-related tumorigenesis.15 Mutations in the
ß-catenin (CTNNB1) gene were previously associated
with pilomatricomas.15,39,40 Other proposed hypotheses
include modified expression of downstream oncogenes
or tumor suppressor genes as a result of abnormal
RNA-splicing, and/or altered protein-coding mecha-
nisms.41–44 Further studies to investigate molecular
mechanisms underlying DM1-related tumorigenesis are
needed to better understand tumor etiology as well as
guide clinical management and therapeutic interventions
in those patients.
To our knowledge, this study is the first to compre-
hensively quantify the risk of developing benign tumors
in DM1 patients. The use of electronic primary care
medical records enabled us to capture the full spectrum
of DM1 patients, minimizing selection bias resulting
from ascertaining patients through tertiary care facilities,
or voluntary registries. Additionally, primary care
records captured data on benign tumors, which are not
routinely collected in inpatient hospitalization records or
cancer registries. Our large sample size, longitudinal
design, and the use of a matched comparison group rep-
resent some of the major strengths of this study.
Nonetheless, several limitations existed, most notably
lack of information on genetic testing or repeat expan-
sion size, which may have led to misclassification of
DM1 status. To minimize this possibility, we only
included patients with diagnostic codes specific to DM1
(described above). Additionally, we conducted several
sensitivity analyses with more stringent definitions of
DM1, and our conclusions remained unchanged, sug-
gesting that diagnostic misclassification did not have a
large impact and demonstrating the robustness of our
findings. It is also possible that the higher frequency of
detected benign tumors in DM1 patients compared with
DM1-free controls may be the result of the relatively
intensive medical care required by DM1 patients. To
address this possibility, all models were adjusted for the
number of healthcare care encounters, and indicators of
health seeking behaviors. Due to incomplete procedure
records, we were unable to conduct analyses restricted
to patients undergoing diagnostic procedures such as
colonoscopy for colon polyps, or imaging studies for
thyroid or brain tumor detection; therefore, validation
of these results in a population with complete procedure
data is important. Notably, the low risks of other benign
tumors equally likely to be affected by detection bias,
such as lipoma and cervical polyps in those patients
provide reassurance that our results are not likely driven
by detection bias. We also observed the occurrence of
pilomatricomas (anecdotally associated with DM1 in
previous literature15) in several patients before their first
DM1 record. Finally, the lack of histopathological data
limited our ability to assess if detected tumors were pre-
malignant and the relatively small number of cancer
events restricted our ability to evaluate site-specific risks
of cancer subsequent to benign tumor.
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The current study suggests a similar organ profile for
benign and malignant tumors in DM1 patients, and that
benign tumors, in patients with the classic subtype of
DM1, may identify those at higher future risk of develop-
ing cancer. These findings, if confirmed, may guide future
studies aiming at understanding mechanisms of DM1-re-
lated tumorigenesis and inform clinical management of
DM1 patients. Our findings highlight the importance of
following population-based screening guidelines as part of
the routine care for DM1 patients.
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